Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,129,000 | 2,693,000 | 1,318,000 | 6,933,000 | 5,900,000 |
| Depreciation Amortization | 2,430,000 | 1,606,000 | 806,000 | 3,267,000 | 2,460,000 |
| Accounts receivable | -424,000 | 37,000 | 233,000 | -68,000 | -409,000 |
| Other Working Capital | -951,000 | -630,000 | -186,000 | -1,519,000 | -1,633,000 |
| Other Operating Activity | -961,000 | -1,360,000 | -1,028,000 | 968,000 | 937,000 |
| Operating Cash Flow | $4,223,000 | $2,346,000 | $1,143,000 | $9,581,000 | $7,255,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -45,000 | -7,000 | -86,000 | N/A | -3,000 |
| PPE Investments | -1,447,000 | -887,000 | -380,000 | -1,777,000 | -1,167,000 |
| Net Acquisitions | -837,000 | -786,000 | N/A | 48,000 | 48,000 |
| Purchase Of Investment | N/A | N/A | N/A | -185,000 | N/A |
| Sale Of Investment | N/A | N/A | N/A | 152,000 | N/A |
| Other Investing Activity | 20,000 | 5,000 | 4,000 | 22,000 | 14,000 |
| Investing Cash Flow | $-2,309,000 | $-1,675,000 | $-462,000 | $-1,740,000 | $-1,108,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -90,000 | -29,000 | -42,000 | 47,000 | 37,000 |
| Debt Issued | 1,000 | 1,000 | N/A | 7,000 | 7,000 |
| Debt Repayment | -1,447,000 | -2,000 | N/A | -753,000 | -753,000 |
| Common Stock Issued | 133,000 | 77,000 | 62,000 | 167,000 | 126,000 |
| Common Stock Repurchased | -968,000 | -966,000 | -540,000 | -3,795,000 | -3,110,000 |
| Dividend Paid | -2,668,000 | -1,780,000 | -890,000 | -3,309,000 | -2,486,000 |
| Financing Cash Flow | $-5,039,000 | $-2,699,000 | $-1,410,000 | $-7,636,000 | $-6,179,000 |
| Exchange Rate Effect | -48,000 | -19,000 | 8,000 | -122,000 | -173,000 |
| Beginning Cash Position | 9,882,000 | 9,882,000 | 9,882,000 | 9,799,000 | 9,799,000 |
| End Cash Position | 6,709,000 | 7,835,000 | 9,161,000 | 9,882,000 | 9,594,000 |
| Net Cash Flow | $-3,173,000 | $-2,047,000 | $-721,000 | $83,000 | $-205,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,223,000 | 2,346,000 | 1,143,000 | 9,581,000 | 7,255,000 |
| Capital Expenditure | -1,447,000 | -887,000 | -380,000 | -1,777,000 | -1,167,000 |
| Free Cash Flow | 2,776,000 | 1,459,000 | 763,000 | 7,804,000 | 6,088,000 |